Evommune Inc. Common Stock (EVMN)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Evommune is a clinical-stage biotech with 48 employees and programs in chronic inflammatory diseases, so its future rests on clinical and regulatory outcomes, not on an established moat. It has no approved product and no demonstrated pricing power. In fiscal 2025, the year ended 2025-12-31, revenue was $13.0M and net loss was $68.9M, or -$11.22 per diluted share. In fiscal 2024, the year ended 2024-12-31, revenue was $7.0M and net loss was $66.8M, or -$45.29 per diluted share. Revenue rose, but losses stayed enormous. More recent filings show fiscal Q1 2026, the quarter ended 2026-03-31, net loss of $21.7M and diluted EPS of -$0.64; fiscal Q2 2026, the quarter ended 2026-06-30, net loss widened to $32.2M and diluted EPS was -$0.89. The FairStock-calculated FCF yield is -35.0%, with trailing free cash flow of -$74.7M, so the company consumes cash. The balance sheet has low reported leverage, D/E 0.03, and Altman Z-Score 4.61, but Piotroski 0/9, ROE -52.11%, and ROCE -31.99% show poor current economics. At $5.88 on 2026-10-13, P/B is 0.77, which may look cheap against book, but book value can evaporate through losses. The P/E of -0.50 is meaningless without earnings. FairStock score 26/100 and no Lynch category—only two years of filed results—reinforce that this is speculative. I would need much clearer evidence of clinical success and a durable path to profitability before seeing a margin of safety.

In plain English: Evommune is a small clinical-stage biotech company trying to develop medicines for chronic inflammatory diseases. It is not profitable: it reported a $68.9 million loss in fiscal 2025 and continues to spend more than it brings in, so the business looks weak on current numbers. The stock closed at $5.88 on 2026-10-13, near the bottom of its 52-week range, and while it trades below its accounting net worth, the continuing losses mean it is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer